Screener
Tarsus Pharmaceuticals, Inc. TARS Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| License fees and collaboration revenue | — | — | 16,667 | — |
| Total revenues | 173,912 | 102,660 | 335,966 | 180,995 |
| Operating expenses: | ||||
| Cost of sales | 12,113 | 6,237 | 21,509 | 11,448 |
| Research and development | 31,010 | 15,594 | 53,361 | 30,003 |
| Selling, general and administrative | 150,697 | 103,013 | 287,126 | 188,008 |
| Total operating expenses | 193,820 | 124,844 | 361,996 | 229,459 |
| Loss from operations before other income (expense) | (19,908) | (22,184) | (26,030) | (48,464) |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s total cost of revenue?
- Tarsus Pharmaceuticals, Inc. (TARS) reported total cost of revenue of $12.11M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s total cost of revenue changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s total cost of revenue increased by 94.2% year-over-year, from $6.24M to $12.11M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude